Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

The Effects of BCMA Expression, Soluble BCMA, and Combination Therapeutics on the Anti-Tumor Activity of HPN217, a BCMA-Targeting Tri-Specific T Cell Engager Against Multiple Myeloma

Patrick P Ng, Wade Aaron, Evan Callihan, Golzar Hemmati, Che-Leung Law, Abdel Kareem Azab, Laura Sun

Blood (2021) 138 (Supplement 1): 1185.

https://doi.org/10.1182/blood-2021-151880

Published: 2021

Journal Articles

Preclinical and Nonclinical Characterization of HPN217: A Tri-Specific T Cell Activating Construct (TriTAC) Targeting B Cell Maturation Antigen (BCMA) for the Treatment of Multiple Myeloma

Che-Leung Law, BSc,PhD, Wade Aaron, Rick Austin, Manasi Barath, Evan Callihan, Thomas Evans, Maria Gamez Guerrero, Golzar Hemmati, Adrie Jones, Kathryn Kwant, Llewelyn Lao, Bryan Lemon, Katrine Moldt, Purbasa Patnaik, Kenneth Sexton, Holger Wesche, Yinghua Xiao, Stephen Yu, Tim Yu

Blood (2018) 132 (Supplement 1): 3225.

https://doi.org/10.1182/blood-2018-99-113921

Published: 2018

Journal Articles

Denintuzumab Mafodotin Stimulates Immune Responses and Synergizes with CD20 Antibodies to Heighten Anti-Tumor Activity in Preclinical Models of Non-Hodgkin Lymphoma

Heather A. Van Epps, PhD, Ryan Heiser, PhD, Anthony Cao, PhD, Kerry Klussman, Changpu Yu, Ivan Stone, Jason Neale, PhD, Shyra J. Gardai, PhD, Che-Leung Law, PhD, Maureen C. Ryan, PhD

Blood (2016) 128 (22): 4177.

https://doi.org/10.1182/blood.V128.22.4177.4177

Published: 2016

Journal Articles

SGN-CD48A: a Novel Humanized Anti-CD48 Antibody-Drug Conjugate for the Treatment of Multiple Myeloma

Tim S. Lewis, PhD, Devra Olson, B.S., Kristine Gordon, B.S., Sharsti Sandall, PhD, Marsha Quick, B.S., Margo Finn, B.S., Lori Westendorf, B.S., Germein Linares, B.S., Chris Leiske, B.S., Albina Nesterova, B.S., Lanshan Huang, B.S., Maitrayee Goswami, B.S., Sa Wang, MD, Che-Leung Law, PhD

Blood (2016) 128 (22): 4470.

https://doi.org/10.1182/blood.V128.22.4470.4470

Published: 2016

Journal Articles

CD27-CD70 interactions in the pathogenesis of Waldenström macroglobulinemia

Allen W. Ho, Evdoxia Hatjiharissi, Bryan T. Ciccarelli, Andrew R. Branagan, Zachary R. Hunter, Xavier Leleu, Olivier Tournilhac, Lian Xu, Kelly O'Connor, Robert J. Manning, Daniel Ditzel Santos, Mariana Chemaly, Christopher J. Patterson, Jacob D. Soumerai, Nikhil C. Munshi, Julie A. McEarchern, Che-Leung Law, Iqbal S. Grewal, Steven P. Treon

Blood (2008) 112 (12): 4683–4689.

https://doi.org/10.1182/blood-2007-04-084525

Published: 2008

Journal Articles

Preclinical Analysis of the Combined Activity of SGN-40, Anti-CD40 Monoclonal Antibody, with Rituximab in Non-Hodgkin Lymphoma.

Timothy S. Lewis, Renee S. McCormick, Julie A. McEarchern, Kim Kissler, Ivan J. Stone, Hans-Peter Gerber, Jonathan G. Drachman, Iqbal Grewal, Che-Leung Law

Blood (2008) 112 (11): 1583.

https://doi.org/10.1182/blood.V112.11.1583.1583

Published: 2008

Journal Articles

Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30

Ezogelin Oflazoglu, Ivan J. Stone, Kristine A. Gordon, Iqbal S. Grewal, Nico van Rooijen, Che-Leung Law, Hans-Peter Gerber

Blood (2007) 110 (13): 4370–4372.

https://doi.org/10.1182/blood-2007-06-097014

Published: 2007

Includes: Supplemental data

Journal Articles

The Humanized Anti-CD40 Monoclonal Antibody, SGN-40, Potentiates Chemotherapy Regimens in NHL Xenograft Models Via Pro-Apoptotic Signaling.

Timothy S. Lewis, PhD, Renee S. McCormick, B.S., Kim Kissler, B.S., Ivan J. Stone, B.S., Mechthild Jonas, Ph.D., May S.K. Sutherland, Ph.D., Hans-Peter Gerber, Ph.D., Jonathan G. Drachman, M.D., Iqbal S. Grewal, Ph.D., Che-Leung Law, Ph.D.

Blood (2007) 110 (11): 2342.

https://doi.org/10.1182/blood.V110.11.2342.2342

Published: 2007

Journal Articles

SGN-33, Lintuzumab, Demonstrates Anti-Leukemic Activity in Preclinical Models of AML.

May S.K. Sutherland, PhD, Changpu Yu, MD, Carol Morris-Tilden, Timothy S. Lewis, PhD, Jamie B. Miyamoto, Julie A. McEarchern, PhD, Ezogelin Oflazoglu, PhD, Hanspeter Gerber, PhD, Eric L. Sievers, MD, Iqbal S. Grewal, PhD, Che-Leung Law, PhD

Blood (2007) 110 (11): 919.

https://doi.org/10.1182/blood.V110.11.919.919

Published: 2007

Journal Articles

Specific Tumor Targeting and Potent Bystander Killing with SGN-35, an Anti-CD30 Antibody Drug Conjugate.

Nicole M. Okeley, Stephen C. Alley, Charles G. Cerveny, Jamie Andreyka, Russell J. Sanderson, Martha Anderson, Dennis R. Benjamin, Che-Leung Law, Eric Sievers, Nathan C. Ihle

Blood (2006) 108 (11): 231.

https://doi.org/10.1182/blood.V108.11.231.231

Published: 2006

Journal Articles

SGN-33 Modulates Cytokine and Chemokine Production by Activated Monocytes and Macrophages.

May S.K. Sutherland, PhD, Timothy S. Lewis, PhD, Changpu Yu, MD, Julie A. McEarchern, PhD, Jonathan G. Drachman, MD, Eric L. Sievers, MD, Iqbal S. Grewal, PhD, Che-Leung Law, PhD

Blood (2006) 108 (11): 1995.

https://doi.org/10.1182/blood.V108.11.1995.1995

Published: 2006

Journal Articles

Targeted Depletion and Inhibition of Activated T Lymphocytes with SGN-70, a Humanized Antibody Specific for the Activation Antigen CD70.

Julie A. McEarchern, PhD, Kerry Klussman, B.S., Tamar E. Boursalian, Ph.D., Iqbal S. Grewal, Ph.D., Che-Leung Law, Ph.D.

Blood (2006) 108 (11): 1728.

https://doi.org/10.1182/blood.V108.11.1728.1728

Published: 2006

Journal Articles

Preclinical In Vitro and In Vivo Evidence Support a Therapeutic Role for the CD70 Directed Monoclonal Antibody (SGN-70) in Waldenström’s Macroglobulinemia (WM).

Evdoxia Hatjiharissi, MD, Allen W. Ho, Lian Xu, Kelly E. O’Connor, Zachary R. Hunter, Daniel D. Santos, MD, Robert Manning, Xavier Leleu, MD, Anne-Sophie Moreau, MD, Christopher J. Patterson, Julie A. McEarchern, PhD, Che-Leung Law, PhD, Iqbal S. Grewal, PhD, Nikhil C. Munshi, MD, PhD, Steven P. Treon, MD, PhD

Blood (2006) 108 (11): 2490.

https://doi.org/10.1182/blood.V108.11.2490.2490

Published: 2006

Journal Articles

SGN-70, a Humanized Anti-CD70 Antibody, Targets CD70-Expressing Hematologic Tumors.

Julie A. McEarchern, PhD, Charlotte F. McDonagh, Ph.D., Leia M. Smith, Ph.D., Kerry Klussman, B.S., Ezogelin Oflazoglu, Ph.D., Carol Morris-Tilden, B.S., Ivan Stone, B.S., Renee McCormick, B.S., Paul Carter, Ph.D., Hanspeter Gerber, Ph.D., Iqbal S. Grewal, Ph.D., Che-Leung Law, Ph.D.

Blood (2006) 108 (11): 2492.

https://doi.org/10.1182/blood.V108.11.2492.2492

Published: 2006

Journal Articles

The Humanized Anti-CD40 Antibody, SGN-40, Promotes Apoptosis Signaling and Is Effective in Combination with Standard Therapies in Lymphoma Xenograft Models.

Timothy S. Lewis, PhD, May S.K. Sutherland, Ph.D., Mechthild Jonas, Ph.D., Charles G. Cerveny, M.S., Renee McCormick, B.S., Alan F. Wahl, Ph.D., Jonathan G. Drachman, M.D., Iqbal S. Grewal, Ph.D., Che-Leung Law, Ph.D.

Blood (2006) 108 (11): 2499.

https://doi.org/10.1182/blood.V108.11.2499.2499

Published: 2006

Journal Articles

Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities

Julie A. McEarchern, Ezogelin Oflazoglu, Leigh Francisco, Charlotte F. McDonagh, Kristine A. Gordon, Ivan Stone, Kerry Klussman, Eileen Turcott, Nico van Rooijen, Paul Carter, Iqbal S. Grewal, Alan F. Wahl, Che-Leung Law

Blood (2006) 109 (3): 1185–1192.

https://doi.org/10.1182/blood-2006-07-034017

Published: 2006

Journal Articles

The Humanized Anti-CD40 Monoclonal Antibody SGN-40 Targets Hodgkin’s Disease Cells through Multiple Mechanisms.

Che-Leung Law, PhD, Julie A. McEarchern, PhD, Charles G. Cerveny, MS, Leia M. Smith, PhD, Albina Nesterova, MS, Kristine A. Gordon, BS, Iqbal S. Grewal, PhD, Alan F. Wahl, PhD

Blood (2005) 106 (11): 1476.

https://doi.org/10.1182/blood.V106.11.1476.1476

Published: 2005

Journal Articles

A Humanized Anti-CD70 Monoclonal Antibody Targets CD70-Expressing Multiple Myeloma.

Julie A. McEarchern, PhD, Charlotte McDonagh, PhD, Allen Ho, BA, Yu-Tzu Tai, PhD, Leigh Francisco, BS, Kerry Klussman, BS, Carol Morris-Tilden, BS, Kristine Gordon, BS, Ezogelin Oflazoglu, PhD, Kim Kissler, Nikhil Munshi, MD, Kenneth C. Anderson, MD, Steven P. Treon, MD, PhD, Paul Carter, PhD, Alan F. Wahl, PhD, Iqbal S. Grewal, PhD, Che-Leung Law, PhD

Blood (2005) 106 (11): 1591.

https://doi.org/10.1182/blood.V106.11.1591.1591

Published: 2005

Journal Articles

The Anti-CD30 Monoclonal Antibody SGN-30 Inhibits Hodgkins Disease Growth and Sensitizes Cells to Established Chemotherapeutics.

Charles G. Cerveny, MS, Che-Leung Law, PhD, Renee S. McCormick, BS, Joel S. Lenox, MS, Kevin J. Hamblett, PhD, Lori E. Westendorf, BS, Andrew K. Yamane, BS, Joseph M. Petroziello, MS, Joseph A. Francisco, PhD, Alan F. Wahl, PhD

Blood (2004) 104 (11): 2639.

https://doi.org/10.1182/blood.V104.11.2639.2639

Published: 2004

Journal Articles

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

Joseph A. Francisco, Charles G. Cerveny, Damon L. Meyer, Bruce J. Mixan, Kerry Klussman, Dana F. Chace, Starr X. Rejniak, Kristine A. Gordon, Ron DeBlanc, Brian E. Toki, Che-Leung Law, Svetlana O. Doronina, Clay B. Siegall, Peter D. Senter, Alan F. Wahl

Blood (2003) 102 (4): 1458–1465.

https://doi.org/10.1182/blood-2003-01-0039

Published: 2003

NARROW

The Effects of BCMA Expression, Soluble BCMA, and Combination Therapeutics on the Anti-Tumor Activity of HPN217, a BCMA-Targeting Tri-Specific T Cell Engager Against Multiple Myeloma

Preclinical and Nonclinical Characterization of HPN217: A Tri-Specific T Cell Activating Construct (TriTAC) Targeting B Cell Maturation Antigen (BCMA) for the Treatment of Multiple Myeloma

Denintuzumab Mafodotin Stimulates Immune Responses and Synergizes with CD20 Antibodies to Heighten Anti-Tumor Activity in Preclinical Models of Non-Hodgkin Lymphoma

SGN-CD48A: a Novel Humanized Anti-CD48 Antibody-Drug Conjugate for the Treatment of Multiple Myeloma

CD27-CD70 interactions in the pathogenesis of Waldenström macroglobulinemia

Preclinical Analysis of the Combined Activity of SGN-40, Anti-CD40 Monoclonal Antibody, with Rituximab in Non-Hodgkin Lymphoma.

Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30

The Humanized Anti-CD40 Monoclonal Antibody, SGN-40, Potentiates Chemotherapy Regimens in NHL Xenograft Models Via Pro-Apoptotic Signaling.

SGN-33, Lintuzumab, Demonstrates Anti-Leukemic Activity in Preclinical Models of AML.

Specific Tumor Targeting and Potent Bystander Killing with SGN-35, an Anti-CD30 Antibody Drug Conjugate.

SGN-33 Modulates Cytokine and Chemokine Production by Activated Monocytes and Macrophages.

Targeted Depletion and Inhibition of Activated T Lymphocytes with SGN-70, a Humanized Antibody Specific for the Activation Antigen CD70.

Preclinical In Vitro and In Vivo Evidence Support a Therapeutic Role for the CD70 Directed Monoclonal Antibody (SGN-70) in Waldenström’s Macroglobulinemia (WM).

SGN-70, a Humanized Anti-CD70 Antibody, Targets CD70-Expressing Hematologic Tumors.

The Humanized Anti-CD40 Antibody, SGN-40, Promotes Apoptosis Signaling and Is Effective in Combination with Standard Therapies in Lymphoma Xenograft Models.

Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities

The Humanized Anti-CD40 Monoclonal Antibody SGN-40 Targets Hodgkin’s Disease Cells through Multiple Mechanisms.

A Humanized Anti-CD70 Monoclonal Antibody Targets CD70-Expressing Multiple Myeloma.

The Anti-CD30 Monoclonal Antibody SGN-30 Inhibits Hodgkins Disease Growth and Sensitizes Cells to Established Chemotherapeutics.

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only